Why the study?
Do non-vitamin K oral anticoagulants reduce the risk of fatal intracranial hemorrhage compared with vitamin K antagonists in patients with non-valvular atrial fibrillation?
Do non-vitamin K oral anticoagulants reduce the risk of fatal intracranial hemorrhage compared with vitamin K antagonists in patients with non-valvular atrial fibrillation?
NOACs significantly reduce the risk of fatal intracranial hemorrhage by more than half compared to VKAs in patients with non-valvular atrial fibrillation.
No takes yet. Share an insight, caveat, or question.
Supports preferring NOACs over VKAs in non-valvular AF to reduce fatal ICH; confirms safety advantage across aggregated trials.
Katsanos et al. (2018) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: